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1. Introduction 
Personalized medications focussed on efficient diagnostic genetics as well as flexible drug 
delivery and targeting (Holmes et al., 2009). A patient-tailored formulation additionally 
includes flexible dose manufacturing techniques that allow accurate and dynamic change of 
dose in response to patient needs. Such an approach may become of significance when a wide 
range of dose or active pharmaceutical ingredient (API) with narrow therapeutic window is 
included in the patient’s therapeutic plan. In addition, financial pressure on healthcare 
systems has encouraged trends of reducing the number of inpatients through providing 
efficient outpatient services such as Telehealthcare (McKinstry et al., 2009; McLean et al., 
2013). It is therefore of great interest to provide an efficient and safe patient-tailored, dose-
controlling system for outpatients which can be remotely and digitally controlled by a 
healthcare provider. 
As oral tablets remain the most popular dosage form for patients, there is an increasing 
demand for a versatile and highly adjustable production method of tablets. Traditional 
methods of tablet manufacture typically require the use of large batches, multiple production 
steps, designated and expensive facilities and experienced operators. The high cost of this 
approach combined with its rigid nature rendered it less suitable a means for preparing 
personalised medicine (Khaled et al., 2014). Ideally, for a production method to address the 
new challenges of personalised medicine, it should be i) highly adjustable, ii) affordable, iii) of 
minimal space requirements, iv) controllable by network and v) safe. 
Several computer-controlled 3D printing approaches have been developed to produce oral 
tablets as an alternative to conventional tableting. The design was based on a laying powder 
bed followed by the deposition of a binder solution from the print-head in a multilayer three 
dimensional fashion (Katstra et al., 2000; Yu et al., 2009; Yu et al., 2007). The proposed 
technology provided rapid dissolving (Yu et al., 2007), extended release (Yu et al., 2009) and 
multi-phase delayed release patterns (Rowe et al., 2000). However, the process required a 
high level of powder flow control, moisture content control, and was limited by the choice of 
binder. Marked improvement could be achieved when considering the accuracy of dosing, 
aesthetic quality of the tablet and the thickness of layer deposition (Sandler et al., 2014a). 
More recently, a bench top 3D printer was utilized to fabricate a bilayer tablet with immediate 
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and extended release pattern (Khaled et al., 2014). However, the slow solidification and 
shrinking of the gel model affected the shape of the finished tablets.  
Fused deposition modelling (FDM) is a widely implemented method for 3D printing of solid 
objects (Lim, 2010). The expiration of patents of this technology is likely to lead to wide 
utilization of the 3D printing by a large number of consumers at a relatively low cost. The 
process uses pre-prepared thermoplastic polymeric filament (typically with a diameter of 1.75 
mm) as an ‘ink’ and passes it through a high temperature nozzle where it is heated to a semi-
liquid state. The software-controlled nozzle deposits the heated material in layer-by-layer 
pattern to form a 3D structure with a typical thickness of 100-300µm. In a rare example, 
Masood (2007) investigated the influence of compactness of a 3D printed model tablets and 
the inter-filament space on dye penetration through the printed tablets. More recently, 
Sandler et al. (2014b) demonstrated the fabrication of an anti-biofilm medical device using a 
3D printer and antibacterial loaded PVA filaments. Goyanes et al. (2014) investigated the 
influence of changing the degree of infill percentage on fluorescein release from cylindrical 
matrix. However, limited research is available on the use of FDM in the fabrication of dosage 
forms as well as the accuracy of weight and dosage of this manufacturing technique.  
The aim of this work is to investigate the feasibility of producing extended-release 
prednisolone tablets as well as controlling the dose via digital manipulation of the printed 
volume. Poly(vinyl alcohol) (PVA) is biodegradable and widely used in the pharmaceutical field 
as an extended release matrix for oral delivery (Carstensen et al., 1981), transdermal patches 
(Wan and Lim, 1992) as well as mucoadhesive and viscosity enhancer for ocular preparations 
(Davies et al., 1991; Wilson et al., 1983). The availably of PVA as a filament for 3D printer 
enabled its use as a model polymer in this study. 
2. Materials and Methods 
 
2.1. Materials 
Prednisolone was purchased from Severn Biotech Ltd (Kidderminster, UK). Polyvinyl alcohol 
(PVA) filaments (melting point 160-170  ͦC, specific heat 0.4 Cal/g ͦC, Density 1.25–1.35 g/cm3) 
were purchased from Reprapcentral (UK). Glycerol, acetonitrile and methanol were supplied 
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by British Drug Houses (BDH, London, UK). Scotch blue painter’s tape 50 mm was supplied by 
3M (Bracknell, UK).  
2.2. Preparation of prednisolone loaded PVA filament 
PVA filaments were loaded with prednisolone via incubation in a saturated solution of 
prednisolone in methanol at 30 °C for 24 hours. After which, the filaments were dried in over 
at 40 ͦC and weighed every 1 hour until a stable weight obtained. To assess loading efficiency, 
three representative samples of PVA (100mg) were incubated in 100 ml of 1:1 methanol: 
water mixture under sonication for 2 hours and were assessed using HPLC as detailed in 
section 2.5. The loading percentage of the filament was calculated as shown in equation 1.  
Loading Percentage (S)=100×
Mass of prednisolone
Total mass of filament
      Equation 1 
 
2.3. Tablet design and printing process 
Blank and drug loaded PVA tablets were designed in an ellipse shape using Autodesk® 3ds 
Max® Design 2012 software version 14.0 (Autodesk, Inc., USA) and saved in STL format 
(Figs.1a and 1b). The design was imported to the 3D printer’s software, MakerWare Version 
2.4.0.17 (Makerbot Industries, LLC., USA) (Fig.1). A series of tablets with increasing volumes 
were printed by modifying the dimensions of the design: length x width x heights (L, H, W) 
without altering the ratios between these dimensions (W = H = 0.4 L). The volume of the 
design (V) was calculated as:  
𝑉 = 𝜋 
𝐿
2 
𝑊
2 
 𝐻 =  0.04 𝜋 𝐿3       Equation 2 
In order to make a correlation between the volume of the design and the mass of the printed 
tablet (M), a series of tablets of increased volume was printed and accurately weighed. A 
linear equation describing this relationship was established:  
𝑀 = 1.0322 𝑉 + 24.898          Equation 3 
since the target dose D (mg) is calculated as: 
   𝐷 = 𝑀. 𝑆/100       Equation 4 
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where M is the mass of the tablet and S is the percentage of loading filament. Therefore, the 
required dimension (L) to achieve a target dose (D) from filament with loading percentage (S) 
can be calculated as: 
𝐿 =   √25
(
100 𝐷
𝑆
)−24.898
1.0322 𝜋
3
       Equation 5 
A series of tablets were printed according to equation 5 to achieve a target dose of 2, 3, 4, 5, 
7.5 or 10 mg. Table 1 illustrated the details of dimensions, expected and measured mass of 
these tablets.  
2.4. Modification of 3D printer 
A MakerBot Replicator® 2X Experimental 3D Printer (MakerBot Industries, New York, USA) 
was utilized to print blank PVA tablets. Blank tablets (PVA only) were printed using default 
settings of the software for PLA filament as follows: type of printer: Replicator 2X; type of 
filament: PLA; resolution: standard; temperature of nozzle: 230°C; temperature of building 
plate: 20 °C; speed of extruder 90 mm/s while extruding and 150 mm/s while traveling; infill: 
100%; height of the layer: 200 µm. No supports or rafts were utilized in the printed model.  
In order to be able to print prednisolone loaded PVA tablets, the following modifications were 
implemented: 
i) Kapton tape layer (default) provided poor adhesion of the designs to the built 
plate. Blue Scotch painter’s tape was applied to the surface of the printing board 
to improve adhesion to the surface layer.  
ii) The filament passed through a plasticizer station containing glycerol before 
entering the heating nozzle. 
iii) Increasing extruder temperature during printing from 230 °C to 250 °C was 
essential to maintain constant flow of prednisolone loaded PVA filament.  
 
 
 
2.5. Determination of drug content  
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In order to assess prednisolone content in drug loaded filaments and the printed tablets, each 
tablet (or 100 mg of filament) was accurately weighed and transferred to a 500 ml volumetric 
flask. Tablets were incubated for 1 hour in 150 ml of distilled water under sonication followed 
by completing the volume with methanol to 500 ml, and subsequent sonication for an 
additional 4 hours at 50 °C. After cooling to room temperature, samples were filtered through 
a 0.22 µm Millex-GP syringe filter (Merck Millipore, USA) and prepared for HPLC analysis. 
Prednisolone concentration was determined through HPLC analysis method using an Agilent 
HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped with Kinetex C18  column 
(100 x 2.1 mm, particle size 2.6 µm) (Phenomenex, Torrance, USA). The mobile phase (water: 
acetonitrile) was used in gradient concentrations: (60:40 at time 0, 40:60 at time 8-12 min 
and 60:40 at time 12.01-14 min) at a flow rate of 0.5 ml/min. The injection volume was set at 
40 µl and the UV detector employed an absorbance wavelength of 250 nm. Temperature of 
the column was maintained at 45 °C and stop time for each sample was 14 min.  
2.6. Scanning Electron Microscopy 
The surface morphology of the PVA filament, extruded filament from the nozzle of the 3D 
printer as well as the printed tablet was assessed using a Quanta-200 SEM microscope at 20 
kV. Samples were placed on metallic stubs and gold coated under vacuum for 2 min using JFC-
1200 Fine Coater (Jeol, Tokyo, Japan), prior to imaging. 
2.7. X-Ray Powder Diffraction  
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to assess 
the crystallinity of prednisolone in the drug loaded tablets. Samples were scanned from 2 
Theta = 5° to 50° using a scan type coupled with a two theta/theta scintillation counter over 
30 min.  
 
 
2.8.  Differential Scanning Microscopy  
A Mettler Toledo DSC823e DSC (Mettler, Switzerland) was utilized to perform thermal 
analysis. Samples of approximately 5 mg were accurately weighed and placed in a 40 µL 
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standard aluminium pan DSC analysis. Analysis was carried on under a nitrogen environment 
(50 mL/min). In order to exclude the effect of humidity, samples were heated to 100 °C for 5 
min then cooled to -20 °C at a rate of 10 °C/min. This was followed by a heat scan from -20 °C 
to 300 °C at a rate of 10 °C/min. All measurements were carried out in triplicates. 
2.9. In Vitro drug release study via flow-through dissolution 
A flow-through cell (Sotax, Switzerland) dissolution apparatus with an open loop system was 
utilized to assess drug release pattern from the 3D printed tablets. The dissolution apparatus 
was connected to piston pumps and a fraction collector (Sotax, Switzerland). Cells of 12 mm 
diameter containing 5 mm glass beads were utilized during the study. Filtration was 
conducted using 25 mm glass microfiber filter discs (FG/B) (Whatman, US) which were placed 
above the cells. The prednisolone loaded tablets were analysed using dissolution media of a 
pH 1.2 (HCl 0.1M) for 2 hours followed by phosphate buffer (pH 6.8) for additional 22 hours 
at 37± 0.5°C. The flow rate was 8ml/min and samples were collected to Sotax fraction 
collector at time intervals 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 15, 18, 21 and 24 hours. 
Samples were further filtered through 0.22 µm Millex-GP syringe filter (Merck Millipore, USA) 
and analysed by HPLC (section 2.5). Three tablets of each strength were assessed.  
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3. Results and discussion 
Ellipse shaped tablets were printed using an FDM 3D printer loaded with original PVA (drug 
free) filament. When a series of PVA tablet with increasing dimensions were printed, a high 
level of correlation was identified between the theoretical volume of the tablet design and 
the mass of the printed tablets (R² = 0.9996). This indicated the ability of FDM 3D printing 
method to achieve a sufficient control of the mass of the printed tablets. Such ability is a key 
advantage for developing a mini-manufacturing unit that can tailor tablet mass by 
manipulating the volume of the design through an input on software. 
In order to investigate the ability of the printed tablet to contain a given dose of API and 
control its release, a model drug needed to be incorporated into PVA filament before loading 
it in the nozzle of the 3D printer. Prednisolone was chosen as a model drug due to its high 
thermal stability and neutral nature. A simple loading process based on incubation in 
methanolic solution was developed. The yielded prednisolone loaded filament showed a drug 
loading of approximately 1.9% w/w. The choice of methanol as a loading solution was based 
on its ability to dissolve the drug and swell PVA without dissolving or damaging the physical 
integrity of the original filament. Other solvents such as ethanol and acetone were found to 
have a degrading effect on the PVA filament or a poor loading efficiency respectively and were 
deemed unsuitable for the loading process. 
When a similar series of tablets were printed with prednisolone loaded PVA filament (Table 
1), the correlation between theoretical volume and the mass of the printed tablet was 
maintained (R² = 0.9983, Equation 2). This signified the potential of FDM 3D printer to 
manufacture a solid tablet with accurate dose, responding to an individual patient’s need 
when minute increment of dosing is required. The finishing quality of prednisolone loaded 
tablets was observed to be similar to blank tablets (made with PVA filaments as received) 
indicating the possibility of adapting a different print setting to suit particular filament 
composition (Fig. 1c).  
The morphology of the PVA filament before and after undergoing fused depositing modelling 
was investigated via SEM imaging. Images of prednisolone loaded PVA filaments (1.75mm) 
showed a smooth surface of the filament (Fig. 2). However, upon extrusion through the 3D 
printer nozzle at an elevated temperature, the surface of extruded filaments (200µm) 
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appeared to be generally rough with irregular pores and voids between layers, this may be 
due to the rapid evaporation of water content and evaporable additives upon exposure to 
high temperature. 
SEM images of surface of prednisolone loaded PVA indicated an irregular and rough surface 
with partially fused filament (Fig. 2). The side of the tablet showed overlaid layers of filament 
with an approximate height of 200 µm. When the inner surface of a 50% printed tablet was 
assessed, the directions of the fused filament were distinct between the peripheral and 
central domains (Fig.3). This might be related to a widely used filling pattern of fused 
filaments dictated by a software (commonly referred to as slicing engine), where a shell 
structure is built to outline the outer surface of the design whilst the central space can be 
either a consistent filling or with one or more empty compartments.  
To establish the ability of such 3D printing method to control dosage, theoretical doses based 
on tablet mass and measured dose of prednisolone in the tablet were compared (Fig. 4). The 
range of dose accuracy was between 88.70% ± 0.79 for 10 mg tablet and 107.71% ± 9.96 for 
3 mg tablet (Table 2). The coefficient of determination between target and achieved dose (R² 
= 0.9905) showed that it is possible to fabricate tablets with desired dose of prednisolone 
through volume modification. The technology holds the potential of digitally controlling a 
patient’s dose via simple software input. It can also be assumed that degradation of 
prednisolone in the nozzle under elevated temperature was minor due to the thermal stability 
of prednisolone at 250 °C (Palanisamy and Khanam, 2011) and the relative short exposure 
time of filament in the nozzle (extrusion speed of 90 mm/s). 
The physical form of prednisolone within the 3D printed tablets was investigated using 
thermal and diffractometry methods. Thermal analysis (DSC) showed prednisolone crystals to 
have a peak at 203 °C corresponding to the melting point of prednisolone (Fig. 5). The 
prednisolone loaded tablet showed a glass transition temperature (Tg) of 45 °C whereas PVA 
filament appeared to have a Tg of 35 °C. It was expected that the Tg of prednisolone loaded 
tablet to be lower than PVA filament due to the plasticizing effect of prednisolone. Such an 
increase in the Tg could be attributed to loss of plasticizer(s) in the PVA during incubation in 
methanol for drug loading. The absence of such an endothermic peak of prednisolone in drug 
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loaded tablets suggested that the majority of prednisolone is in amorphous form within the 
PVA matrix. 
On the other hand, XRPD indicated typical peaks of prednisolone at 2Theta = 8.7, 14.7 and 
18.6 (Fig. 6) (Nishiwaki et al., 2009). The absence of such peaks in prednisolone loaded tablets 
suggested that the majority of prednisolone exists in amorphous form. Both blank PVA 
filament and drug loaded PVA tablets showed peaks at 2Theta = 9.3°, 18.7° and 28.5°. Such 
peaks may be related to the semi-crystalline structure of PVA (Gupta et al., 2011). As the exact 
PVA filament composition was not disclosed by the manufacturer, it was not possible to 
attribute these peaks. 
In vitro release pattern of prednisolone from 3D printed PVA tablets was studied via a pH-
change flow-through cell dissolution system. Fig. 7 indicated that prednisolone tablets with 
different weights exhibited a similar in vitro release profile. The majority of drug release 
(>80%) took place after 12 hours for 2 and 3 mg tablets and over 18 hours for tablets with 
doses of 4, 5, 7.5 and 10 mg. Approximately 100% of prednisolone release was attained within 
16 hours for tablets with 2 and 3 mg drug loading. The faster release of prednisolone from 
the smaller size tablets is likely to be related to their larger surface area/mass ratio which 
promotes both drug diffusion and the erosion of PVA matrix. By the end of the dissolution 
test (24 hours), it was visually evident that the tablet had completely eroded within the flow-
through cell. Several studies reported PVA to form a hydrogel system where drug release is 
governed by an erosion mechanism (Vaddiraju et al., 2012; Westedt et al., 2006).  
In summary we have reported a significant adaptation of a bench top FDM 3D printer for 
pharmaceutical applications. The resultant tablets were solid structures with a regular ellipse 
shape and adjustable weight/dose through software control of the design’s volume. This 
fabrication method is applicable to other solid and semisolid dosage forms such as implants 
and dermal patches.  
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4. Conclusion 
FDM based 3D printing was adapted to engineer and control the dose of extended release 
tablets. Prednisolone loaded PVA filament demonstrated the ability to be printed into ellipse 
shaped tablets using 3D printer. The mass of a printed tablet was digitally controlled by 
manipulating the design’s volume through computer software. The precision of dose control 
ranged between 88.7%-107%. Thermal analysis and XRPD suggested that the majority of 
prednisolone exists in amorphous form within the PVA matrix while prednisolone release 
from a 3D printed tablet was extended over 24 hours. In principle, FDM 3D printers can be 
exploited as a platform to construct flexible dose tablets from purpose-built drug-containing 
filaments.  
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Table 1: The target dose, dimensions, theoretical volume, theoretical and measured mass of prednisolone loaded PVA tablets  
Tablet target 
dose (mg) 
Dimensions 
(L x W x H) (mm) 
Tablet theoretical volume 
(mm3) 
Tablet theoretical mass (mg) Tablet measured mass (mg)± 
SD  
2 8.39x3.36x3.36 74.23 101.52 102± 1.73 
3 10.11x4.04x4.04 129.66 158.73 168.30±1.43 
4 11.29x4.52x4.52 180.92 211.64 216.18±1.01 
5 12.34x4.94x4.94 236.31 268.82 283.44±5.03 
7.5 14.00x5.60x5.60 344.71 380.71 396.67±4.93 
10 15.50x6.20x6.20 467.66 507.61 498.67±5.69 
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Table 2: The target dose, filament drug loading, theoretical and measured dose, and dose accuracy of prednisolone loaded PVA tablets 
Tablet target 
dose (mg) 
Filament drug loading 
(%) 
Theoretical dose (mg) 
±SD 
Measured dose (mg) 
±SD 
Dose accuracy (%) 
±SD 
CV (%) 
2 1.97 2.01±0.03 1.98±0.10 98.67±3.43 3.48 
3 1.89 3.18±0.03 3.43±0.34 107.71 ± 9.96 9.25 
4 1.89 4.09±0.02 4.37±0.11 107.06±2.98 2.79 
5 1.86 5.27±0.09 5.27±0.22 99.95±2.51 2.51 
7.5 1.97 7.81±0.10 6.99±0.22 89.49±2.37 2.65 
10 1.97 9.82±0.11 8.71±0.17 88.70±0.79 0.89 
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